Outcome Measures
adverse events, blood pressure, penile tumescence, anxiety
The primary outcome was change in brain activity on whole-brain analysis as determined by fMRI blood oxygen level–dependent (BOLD) activity in response to visual sexual stimuli during kisspeptin administration compared with placebo. Secondary outcomes were as follows: changes in behavioral measures of sexual desire and arousal, general mood, anxiety, and nonsexual attention; correlation analyses between brain activity in a priori–defined regions of interest (ROIs) and psychometric scores; changes in physiological arousal as measured by penile tumescence; and changes in hormone levels during kisspeptin administration compared with placebo. Safety assessments included adverse events, blood pressure, and heart rate recordings.